Organon & Co. (BMV:OGN)

Market Cap	61.16B +37.0%
Revenue (ttm)	111.10B -2.1%
Net Income	4.43B -67.2%
EPS	16.99 -67.2%
Shares Out	n/a
PE Ratio	13.79
Forward PE	3.97
Dividend	1.43 (0.58%)
Ex-Dividend Date	May 11, 2026

Volume	n/a
Average Volume	786
Open	245.00
Previous Close	245.00
Day's Range	245.00 - 245.00
52-Week Range	106.15 - 245.00
Beta	n/a
RSI	73.66
Earnings Date	Apr 30, 2026

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote develo...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: OGN

Financial Performance

In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.

Financial numbers in USD